These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 22931329

  • 21. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 22. Natalizumab treatment for multiple sclerosis.
    Ferreira ML.
    Arq Neuropsiquiatr; 2014 Dec; 72(12):911-2. PubMed ID: 25517640
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M.
    Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B, Sandrock A, Panzara MA.
    N Engl J Med; 2005 Jul 28; 353(4):432-3. PubMed ID: 15947083
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
    Tyler KL, Khalili K.
    Rev Neurol Dis; 2005 Jul 28; 2(3):144-9. PubMed ID: 16400315
    [No Abstract] [Full Text] [Related]

  • 29. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar 28; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 30. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 31. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.
    J Neurol Neurosurg Psychiatry; 2014 Oct 01; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract] [Full Text] [Related]

  • 32. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 33. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug 15; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 34. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
    Berger JR, Koralnik IJ.
    N Engl J Med; 2005 Jul 28; 353(4):414-6. PubMed ID: 15947082
    [No Abstract] [Full Text] [Related]

  • 35. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L.
    Eur J Neurol; 2023 Oct 28; 30(10):3357-3361. PubMed ID: 37485841
    [Abstract] [Full Text] [Related]

  • 36. Natalizumab for relapsing multiple sclerosis.
    Meyer MA.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract] [Full Text] [Related]

  • 37. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP, Verhoeff L, Zentjens W, Killestein J, van Munster ET, Barkhof F, van Eijk JJ.
    J Neurol Neurosurg Psychiatry; 2013 Oct 01; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract] [Full Text] [Related]

  • 38. JC viremia in natalizumab-treated patients with multiple sclerosis.
    Major EO, Frohman E, Douek D.
    N Engl J Med; 2013 Jun 06; 368(23):2240-1. PubMed ID: 23738566
    [No Abstract] [Full Text] [Related]

  • 39. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA, Weinstock-Guttman B.
    Mult Scler Relat Disord; 2016 Sep 06; 9():54-5. PubMed ID: 27645344
    [Abstract] [Full Text] [Related]

  • 40. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 06; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.